S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammation by Inhibiting IL-6/STAT3 Pathway

Minjun Wang\(^1,3\), Wenbo Tang\(^2\), Hong Xin\(^1\), Yi Zhun Zhu\(^1,3\)*

1 Shanghai Key Laboratory of Bioactive Small Molecules, Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, 201203, China, 2 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China, 3 Department of Pharmacology, School of Pharmacy, Macau University of Science & Technology, Macau, China

☯ These authors contributed equally to this work.
* zhuyz@fudan.edu.cn; yzzhu@must.edu.mo

Abstract

Anemia of inflammation (AI) is clinically prevalent and greatly threatens public health. Traditional remedies have raised controversy during clinical practice, calling for alternative therapies. We have recently found that hydrogen sulfide (H\(_2\)S) inhibits inflammatory hepcidin, the critical mediator of AI. However, due to the chemical property of H\(_2\)S, there remains an urgent need for a stable H\(_2\)S donor in AI treatment. Here we reported that S-propargyl-cysteine (SPRC), a novel water-soluble H\(_2\)S donor, suppressed hepatic hepcidin and corrected hypoferremia induced by lipopolysaccharide. The effects of SPRC were reversed by inhibition of cystathionine \(\gamma\)-lyase, one of the major endogenous H\(_2\)S synthases. Moreover, SPRC reduced serum hepcidin, improved transferrin saturation, and maintained erythrocyte membrane integrity in a chronic mouse AI model. Consistently, splenomegaly was ameliorated and splenic iron accumulation relieved. Mechanism study indicated that serum IL-6 content and hepatic \(\text{IL-6 mRNA}\) were decreased by SPRC, in parallel with reduced hepatic JAK2/STAT3 activation. On the whole, our data reveal the inhibition of inflammatory hepcidin by SPRC, and suggest SPRC as a potential remedy against AI.

Introduction

Anemia of inflammation (AI) is the second most prevalent anemia after anemia of iron deficiency [1]. Since AI is often accompanied by chronic diseases, such as cancer, chronic infections, and auto-immune syndrome, it is also named as anemia of chronic diseases. Despite the fact that AI is relatively mild (hemoglobin levels between 90–120 g/L), mounting evidences have revealed its relation to poor prognosis and increased mortality [2, 3]. In addition,
concerns have arisen with respect to the effectiveness and safety of conventional therapies [4, 5], spurring the search for alternative remedies for AI.

It is currently well established that AI is a chronic inflammatory disease in nature. Hepcidin, a hepatic iron-regulatory hormone, acts as the prominent modulator of AI [6]. Incremental hepcidin production is observed in AI patients [7], while inhibition of hepcidin protects mice from AI [8]. Previous studies have demonstrated that inflammatory hepcidin is induced by IL-6-mediated hepatic JAK2/STAT3 activation [9]. Phosphorylated STAT3 dimer directly binds to hepcidin promoter and activates its transcription [10]. Increased hepcidin levels suppress dietary iron absorption and promote iron retention in spleen and liver, thus lower circulating iron content and inhibit erythropoiesis. Therefore, inhibiting inflammatory hepcidin by blocking IL-6/JAK2/STAT3 pathway is believed as a novel approach to treating AI.

Hydrogen sulfide (H\(_2\)S) is the third gasotransmitter and tightly involved in various pathophysiological conditions [11, 12]. H\(_2\)S is endogenously produced by at least 3 enzymes, including cystathionine \(\gamma\)-lyase (CSE), and exerts regulatory effects in inflammation [13]. In our recent work, we reported for the first time that sodium hydrosulfide (NaHS), an exogenous H\(_2\)S donor, inhibited inflammatory hepcidin and relieved hypoferremia induced by acute inflammation [14]. However, NaHS releases H\(_2\)S in a robust and transient manner [15], thus is more a pharmacological reagent than a potential remedy. This prompted us to investigate other sustained-releasing H\(_2\)S donors. S-propargyl-cysteine (SPRC) is an analog of S-allyl-cysteine (SAC), an H\(_2\)S donor originally derived from garlic extract [16]. Similar to SAC, SPRC serves as a substrate of CSE and increases endogenous H\(_2\)S production. Compared with NaHS, SPRC is more chemically stable and releases H\(_2\)S in a slower and more sustained manner, with a half-life of about 3 h in rats [17], and about 16 h in Beagle dogs [18]. As an H\(_2\)S donor, SPRC elicits extensive regulation on pathological conditions. Many studies have been published reporting the protective effects of SPRC in ischemia/hypoxia injury [19], angiogenesis [20], cognitive impairment [21], and acute pancreatitis [22]. But so far no research has been done regarding its effects on inflammatory hepcidin and iron balance. Moreover, there remains a gap of knowledge concerning the effects of H\(_2\)S donors on chronic AI.

In the present study, we aimed to evaluate the effects of SPRC on inflammatory hepcidin, and assessed its therapeutic potential against AI. We discovered that SPRC, by inhibiting IL-6/JAK2/STAT3 pathway, could reduce inflammatory hepcidin activation in vivo both in acute and chronic AI models. Our results indicate SPRC as a potential drug, and throw light on novel treatment strategy for AI.

**Materials and Methods**

**Compounds and reagents**

SPRC (Fig 1A) was synthesized by the reaction of L-cysteine and propargyl bromide, followed by recrystallization to reach 99% purity as described previously [19]. NaHS, lipopolysaccharide (LPS), propargylglycine (PAG), turpentine, and 1, 10-phenanthroline monohydrate were all purchased from Sigma-Aldrich, St. Louis, MO, USA.

**Animals**

All animal experimental protocols complied with the Animal Management Rules of the Ministry of Health of the People’s Republic of China, and were approved by the Animal Care Committee of Fudan University (No. 13111243). Mice were sacrificed after anesthesia with pentobarbital sodium. Every effort was made to ameliorate animal sufferings during the experiments.
Eight-week-old male C57BL/6 mice (about 20 g/each) were purchased from Sippr-bk Experimental Animal Center, Shanghai, China. Mice were housed under specific pathogen-free (SPF) rooms at 25°C and maintained under a 12-h/12-h light/dark cycle with ad libitum access to food and water.

Acute LPS model and chronic turpentine model

To evaluate the effects of SPRC on hepatic hepcidin and hypoferremia during acute inflammation, C57BL/6 mice were i.p. injected with 10 mg/kg SPRC daily for 1 week. Meanwhile, PAG (15 mg/kg, i.p.) was applied with SPRC to inhibit CSE-mediated H$_2$S production, while NaHS (6 mg/kg, i.p.) served as a positive control for 3 days. The doses for PAG and SPRC were chosen by reference to previous reports [22, 23]. One hour after the last injection, mice were challenged with 0.5 mg/kg LPS (i.p.) and sacrificed 6 h later after anesthesia with pentobarbital sodium. Normal saline was used as vehicle control.

For turpentine model, C57BL/6 mice were subcutaneously injected with turpentine (100 μl/20 g weight) once a week for 4 weeks to induce chronic AI. SPRC (i.p., 10/20 mg/kg) was administrated twice a week, starting from the second injection of turpentine. Mice were sacrificed on the fifth week after anesthesia with pentobarbital sodium. PAG significantly increased mortality in this model, thus was not applied here.

RNA isolation and real-time qRT-PCR

Total RNA from mouse livers was extracted using RNAiso Plus (TAKARA Bio, China) according to the manufacturer's instructions. Reverse transcription of total RNA was carried out with PrimeScript™ RT Master Mix (Perfect Real Time, TAKARA Bio, China). Real-time qPCR was performed with Bio-Rad CFX ConnectTM Real-Time PCR System and primers as follows: murine $\beta$-actin forward 5'-TGTTACCAACTGGGACGAC-3', reverse 5'-GGTGTTGAAGGTTCTCAAA-3'; murine Hamp forward 5'-AGAGCTGCAGCCTTTGCAC-3', reverse 5'-GAAATGGGGAAGTCTTCTCA-3'; murine Il-6 forward 5'-TGTGCAATGGCAATTCTGAT-3', reverse 5'-CCAGAGGAAATTTTCAATAGGC-3'; murine suppressor of cytokine signaling 3 (Socs3) forward 5'-TGCCGCTCAAGACCTTCAG-3', reverse 5'-GCTCCAGATGAAATCCGC-3'; murine serum amyloid A 2 (Saa2) forward 5'-TGCTGGAGAAATCGGAGAC-3', reverse 5'-AAAGCTCTCCTTGTCACT-3'; Specificity of all PCR products was confirmed by melting curve analysis.

Immunoblot analysis

For SDS-PAGE, mouse liver tissues were homogenized in RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS, pH 7.4) containing protease and phosphatase inhibitor cocktails (Sigma-Aldrich). Fifty micrograms of protein were subjected to SDS-PAGE gels for each sample, and transferred to PVDF membranes (Millipore, Bedford, MA, USA) followed by blocking with 5% skim milk and incubation with primary antibodies overnight at 4°C. Antibodies to total JAK2, total and phosphorylated JAK2.
STAT3 (Tyr705) were obtained from Cell Signaling Technology Beverly, MA USA. Antibody to phosho-JAK2 (Tyr221) was acquired from Bioworld Technology, Louis Park, MN, USA. Antibody to GAPDH was obtained from Proteintech Group, Chicago, IL, USA. Immunoreactive proteins were visualized and quantified by densitometry using a Bio-Rad Image Lab system. GAPDH served as the loading control.

**Serum iron, hepcidin and IL-6 analysis**

Mouse blood samples were collected in non-heparinized tubes, allowed to stand for 2 h at room temperature, and then centrifuged at 3000 rpm for 10 min to separate serum. Serum iron content and total iron-binding capacity (TIBC) were determined by commercial kits according to protocols described by Jiancheng Bioengineering Institute, China. Transferrin saturation was calculated as serum iron/TIBC × 100%.

Murine serum hepcidin and IL-6 were quantified using ELISA kits from USCN (China) and Boatman (China), respectively.

**Quantification of H₂S concentration**

H₂S determination was conducted by the methylene blue method as described previously [23].

**Tissue non-heme iron analysis**

Non-heme iron of mouse spleen was determined using 1,10-Phenanthroline monohydrate as described previously [14]. In brief, dried spleen tissues were digested in acid solutions (3M hydrochloric acid and 10% trichloroacetic acid). After centrifuge, the supernatant was mixed with 1,10-Phenanthroline, and the absorbance at 510 nm was measured using a spectrophotometer.

**Wright-Giemsa staining and Perl’s Prussian blue staining**

Peripheral blood smears were performed with 3 μl fresh EDTA-treated whole blood, and stained with Wright-Giemsa solution (Yeasen Biotech, China). The slides were then visualized with Zeiss Axio Scope A1 system.

Mouse spleen tissues were fixed in 4% formalin PBS solution, embedded in paraffin wax, sectioned, and stained with Perl’s Prussian blue solution for 30 min at room temperature. A neutral red counterstain was then applied to provide a contrasting background. Images were captured using Zeiss Axio Scope A1 system.

**Statistical analysis**

Data are expressed as the mean ± SEM. Statistical analysis was performed with one-way ANOVA followed by Turkey’s test. A two-tailed p < 0.05 was considered statistically significant.

**Results**

**SPRC reduces inflammatory hepcidin expression by suppressing IL-6/JAK2/STAT3 pathway in vivo**

In the absence of LPS challenge, treatment of SPRC and NaHS alone elicited no significant effects on hepatic hepcidin and serum iron (Fig 1B and 1C). As demonstrated in Fig 1D, pretreatment of SPRC and NaHS significantly increased serum H₂S levels, as opposed to SPRC + PAG. By performing qRT-PCR and ELISA, we analyzed hepatic hepcidin mRNA expression...
and serum hepcidin levels, and found that both SPRC and NaHS inhibited hepcidin activation, which was exacerbated by PAG (Fig 1E and 1F). Consistent results were observed with serum iron concentration (Fig 1G).

Considering the dominant role IL-6/STAT3 plays in inflammatory hepcidin induction, we then assessed whether SPRC modulated IL-6 production and JAK2/STAT3 pathway. As expected, SPRC and NaHS markedly reduced serum IL-6 levels by more than 50%, which was abrogated by PAG (Fig 2A). To better evaluate the regulation of local inflammation in the liver, we examined hepatic Il-6 and Tnfa mRNA expression and got similar results (Fig 2B and 2C). The minor differences between serum IL-6 content and hepatic IL-6 levels could be attributed to different systemic and local inflammatory status. Moreover, SPRC successfully suppressed hepatic JAK2/STAT3 phosphorylation (Fig 2D–2F). Consistent data were obtained with the expression of suppressor of cytokine signaling 3 (Socs3) and serum amyloid A 2 (Saa2), two target genes of STAT3 (Fig 2G and 2H). These data indicate that SPRC, as an endogenous H2S donor, in part ameliorates inflammatory hepcidin and hypoferremia by inhibiting IL-6/JAK2/STAT3 pathway.

**SPRC improves turpentine-induced AI in vivo**

We next investigated whether SPRC could treat chronic AI. Turpentine has been widely used to induce inflammatory models for decades, including normocytic, normochromic anemia which shares the same nature clinically [24–26]. The work flow is demonstrated in Fig 3A. As was observed in LPS model, SPRC decreased serum hepcidin levels in the turpentine model (Fig 3B). Although the hepatic hepcidin mRNA levels were relatively low, which might be attributed to the late detection time from the last turpentine injection as reported previously [24], there remained a decreasing trend in the SPRC groups (Fig 3C). No significant change was observed in total iron binding capacity (Fig 3D). As to serum iron and transferrin (Tf) saturation, both doses of SPRC exerted similar treatment effects while SPRC 20 was more pronounced (Fig 3E and 3F). To further assess the effects of SPRC on hemogram, complete blood count was conducted. As illustrated in Table 1, SPRC increased erythrocyte number, hemoglobin content, in addition to hematocrit levels. By performing blood smears and Wright-Giemsa staining, we found that SPRC improved erythrocyte membrane regularity (Fig 3G). These results suggest that SPRC successfully relieves turpentine-induced AI symptoms.

**SPRC ameliorates turpentine-induced AI by blocking IL-6/JAK2/STAT3 pathway**

The results above prompted us to ask whether IL-6/STAT3 pathway was inhibited by SPRC in AI model. As presented in Fig 4A and 4B, both serum IL-6 content and hepatic IL-6 mRNA levels were induced, but in a much smaller extent than that in the LPS model. Although serum IL-6 was not significantly changed by SPRC, hepatic IL-6 mRNA expression was suppressed, as was observed previously. Accordingly, hepatic JAK2/STAT3 activation was suppressed by SPRC treatment (Fig 4C–4E). Taken together, we conclude that SPRC improves turpentine-induced AI by inhibiting IL-6/JAK2/STAT3 pathway.

**SPRC ameliorates splenomegaly and reduces splenic iron accumulation during AI**

The spleen plays an important role in immune response, and chronic inflammation is often accompanied by splenomegaly. On the other hand, besides reduced circulating iron level,
Dysregulation of splenic iron is another hallmark of AI [1]. Thus we turned attention to the effects of SPRC on spleen during chronic AI. As manifested in Fig 5A and 5B, SPRC partially relieved splenomegaly induced by turpentine. Moreover, tissue iron determination indicated that splenic iron accumulation was in part reversed by SPRC (Fig 5C). Similar results were obtained by Perl's Prussian blue staining with mouse spleen sections (Fig 5D).

Fig 2. SPRC reduces inflammatory hepcidin activation by inhibiting IL-6/JAK2/STAT3 pathway. (A) SPRC and NaHS markedly decreased serum IL-6 levels induced by LPS (n = 5). (B-D) Hepatic Il-6, Tnfa mRNA levels and JAK2/STAT3 phosphorylation were induced by LPS, and suppressed by SPRC and NaHS. Moreover, PAG diminished the effects of SPRC (n = 5). (E-F) Densitometry analysis of Fig 2D. (G-H) Hepatic mRNA levels of Socs3 and Saa2, two target genes of STAT3 (n = 5). Representative immunoblots are presented. Whole uncropped images of Fig 2D are shown in S1 Fig. Data are presented as the mean ± SEM. ### p < 0.001 compared with the control group; * p < 0.05, ** p < 0.01, *** p < 0.001, compared with the LPS group; @ p < 0.05, @@ p < 0.01, @@@ p < 0.001.

doi:10.1371/journal.pone.0163289.g002
SPRC Inhibits Hepcidin and Relieves Anemia of Inflammation

(A) Treatment schedule: Tur - turpentine

(B) Serum hepcidin levels:
- saline
- turpentine

(C) Hspa8 mRNA expression:
- saline
- turpentine

(D) TIBC levels:
- saline
- turpentine

(E) Serum iron levels:
- saline
- turpentine

(F) Tt saturation (%):
- saline
- turpentine

(G) Bone marrow images:
- con
- Tur
- Tur + SPRC 10
- Tur + SPRC 20

PLOS ONE | DOI:10.1371/journal.pone.0163289 September 20, 2016 8 / 15
In the present study, we demonstrated that SPRC, a novel water-soluble H\textsubscript{2}S donor, exerted inhibition on inflammatory hepcidin. Moreover, SPRC not only relieved hypoferremia induced by acute inflammatory insult, but also improved chronic AI symptoms \textit{in vivo}. Mechanism study indicated that the effects of SPRC were related to decreased IL-6 production, reduced inflammation, and suppressed hepatic JAK2/STAT3 activation. Our results provide new insights into the anti-inflammatory property of H\textsubscript{2}S donors, and suggest new approach for drug development against AI.

AI is one of the most common complications in patients with chronic inflammation. It is estimated that the prevalence of AI is 18–95\% in infections, 30–77\% in cancer, and 8–71\% in autoimmune diseases \cite{1}. However, AI is often unrecognized thus needs appropriate intervention and specific care \cite{27, 28}. Mounting evidences have indicated the relation between anemia and increased cardiovascular risk, higher mortality and poor prognosis \cite{29, 30}. Moreover, normalization of anemia is associated with improved quality of life \cite{31}. Nevertheless, conventional therapies for AI have raised clinical concerns, such as infection risk induced by iron supplement and increased mortality in cancer patients on erythropoietic stimulating agents \cite{32, 33}, illustrating an urgent need for alternative remedy of AI. In our study, we identified SPRC, a sustained-releasing H\textsubscript{2}S donor, suppressed inflammatory hepcidin and acted as a potential

![Discussion](image)

**Table 1. Hematological and mouse indices.**

| Parameter          | con       | model     | Turpentine |
|--------------------|-----------|-----------|------------|
| RBC (×10\textsuperscript{12}/L) | 9.86 ± 0.21 | 7.94 ± 0.55\*\#\#\# | 9.02 ± 0.56* | 9.10 ± 0.67** |
| HGB (g/L)          | 138 ± 3   | 110 ± 9\#\#\# | 122 ± 9*    | 126 ± 11*      |
| HCT (%)            | 44.3 ± 0.5| 36.1 ± 2.6\#\#\# | 40.3 ± 3.0* | 41.2 ± 3.6*    |
| MCV (fL)           | 45.5 ± 0.6| 46.5 ± 1.2 | 46.2 ± 0.5 | 47.2 ± 1.3     |
| MCH (pg)           | 14.1 ± 0.1| 13.7 ± 0.5 | 13.8 ± 0.3 | 14.0 ± 0.2     |
| PLT (×10\textsuperscript{9}/L) | 1263 ± 118 | 1557 ± 378 | 1857 ± 217 | 1442 ± 221     |
| RDW-SD (fL)        | 25.9 ± 0.4| 31.1 ± 3.7 | 29.7 ± 1.4 | 31.9 ± 5.5     |
| Neutrophil (×10\textsuperscript{9}/L) | 1.18 ± 0.59 | 2.28 ± 1.39 | 1.66 ± 1.14 | 1.01 ± 0.17* |
| Lymphocyte (×10\textsuperscript{9}/L) | 5.79 ± 2.27 | 4.45 ± 1.21 | 3.94 ± 1.72 | 3.58 ± 1.78    |
| Monocytes (×10\textsuperscript{9}/L) | 1.22 ± 0.36 | 2.18 ± 1.61\* | 2.14 ± 0.85 | 3.45 ± 3.64    |
| Mouse (g)          | 26.0 ± 1.0 | 26.0 ± 1.6 | 25.3 ± 0.6 | 26.2 ± 1.8     |

RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; PLT, platelet; RDW, red blood cell distribution width. Data are presented as the mean ± SD.

\* \( p < 0.05 \)

\# \( p < 0.005 \)

\#\#\# \( p < 0.001 \) compared with the control group

\* \( p < 0.05 \)

\** \( p < 0.01 \), compared with the model group.

doi:10.1371/journal.pone.0163289.t001
therapeutic compound for AI. SPRC successfully relieved iron disturbance and reduced hemoglobin levels in vivo, the two hallmarks of AI. More work is needed to assess the druggability of SPRC.

**Fig 4.** SPRC improved AI by reducing hepatic IL-6/JAK2/STAT3 activation. (A) Serum IL-6 content was not significantly changed by SPRC (n = 7). (B) Hepatic IL-6 mRNA levels were suppressed by SPRC, though only 2-fold change was observed in the model group (n = 7). (C) SPRC successfully ameliorated hepatic JAK2/STAT3 phosphorylation in the turpentine model. (D-E) Densitometry analysis of Fig 5C. Representative immunoblots are presented. Whole uncropped images of Fig 4C are shown in S2 Fig. Data are presented as the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control group; * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the model group.

doi:10.1371/journal.pone.0163289.g004
Fig 5. SPRC reduces splenomegaly and corrects splenic iron accumulation in chronic AI model. (A) Representative images indicated relieved splenomegaly by SPRC. (B) Consistent results were observed with mouse spleen weight (n = 7). (C-D) Splenic iron accumulation was relieved by SPRC, as assessed by non-heme iron analysis and Perl's Prussian blue staining (n = 7). Representative images are presented. Data are presented.
Hepcidin, initially named after its antimicrobial property, was first discovered in human urine [34]. Following studies reveal its critical role in iron balance and its regulation by IL-6/STAT3 pathway [9, 35]. During inflammation, phospho-STAT3 dimers directly bind to the promoter region of hepcidin, initiating its transcription [35]. By promoting the degradation of ferroportin, the prominent cellular iron exporter, hepcidin cuts down dietary iron absorption, induces iron retention within liver and spleen, and reduces circulating iron levels. It has been well demonstrated that hepcidin plays the key role in the development of AI [6], making it an ideal therapeutic target for iron-restrictive anemia. In principle, hepcidin antagonists either suppress hepcidin expression induced by upstream signaling, or inhibit iron-regulating effects triggered by hepcidin. For the former strategy, it is particularly effective to decrease cytokine production, typically IL-6, and block related signaling pathway. Indeed, several studies have focused on bone morphogenetic proteins or IL-6 pathways and identified some potential hepcidin antagonists [36–38]. In accordance, our results demonstrated SPRC as a potent inhibitor of IL-6 production and hepcidin activation, making it a strong candidate for hepcidin antagonists.

H₂S used to be regarded as a noxious gas, until recent recognition as the third gasotransmitter. Cystathionine γ-lyase (CSE) and cystathionine-β-synthase (CBS) are two major endogenous H₂S synthases mainly expressed in heart and brain. Incremental studies have reported the involvement of H₂S in cardiovascular system, central nervous system, and inflammation [11, 39, 40]. Several researches from independent groups have indicated the protective property of H₂S by preserving mitochondrial function during myocardial infarction [41, 42]. Gong et al. suggests that H₂S attenuates lipopolysaccharide-induced cognitive impairment in rats [43]. In accordance with our previous observation that NaHS suppresses inflammation and reduces IL-6 secretion, Whiteman et al. claims reduced IL-6 production by H₂S application [15], which is probably attributed to inhibition of NF-κB [44]. On the other hand, very few studies are available regarding H₂S and iron metabolism. In our recent work, we demonstrates that NaHS, an exogenous H₂S donor, inhibits hepcidin and relieves hypoferremia induced by LPS [14]. Consistently, SPRC, a CSE-dependent endogenous H₂S donor, showed similar effects in vivo, supporting the anti-inflammatory effects of H₂S.

As an H₂S donor, SPRC shows multiple regulation in different disease models. A number of studies have revealed its therapeutic potential in cardiovascular system [20, 45] and inflammation [22, 46]. Consistent with previous observations, here we demonstrated corrected iron disturbance and relieved AI symptoms by SPRC. Our work broads the potential application of SPRC, and provides new evidence of the gasotransmitter role of H₂S.

Conclusions
SPRC, a novel H₂S donor, relieves hypoferremia and anemia both in acute and chronic models of inflammation. The effects of SPRC were attributed to inhibited hepatic JAK2/STAT3 activation and reduced hepcidin production. Our results provide new insights into the anti-inflammatory property of H₂S, and suggest SPRC as a potential remedy against AI.

Supporting Information
S1 Fig. Whole uncropped images of the original western blots for Fig 2D. Whole uncropped images of the original western blots for p-JAK2 (A), JAK2 (B, ten lanes from the right are...
used), p-STAT3 (C), STAT3 (D), and GAPDH (E) in Fig 2D.

S2 Fig. Whole uncropped images of the original western blots for Fig 4C. Whole uncropped images of the original western blots for p-JAK2 (A), JAK2 (B, ten lanes from the right are used), p-STAT3 (C), STAT3 (D), and GAPDH (E) in Fig 4C.

Acknowledgments
We thank Dr. Lei Miao for technical assistance in animal experiments.

Author Contributions
Conceptualization: MW YZZ.
Formal analysis: MW HX.
Funding acquisition: YZZ.
Investigation: MW WT.
Methodology: MW HX.
Project administration: MW.
Supervision: YZZ.
Validation: WT.
Visualization: MW.
Writing – original draft: MW WT.
Writing – review & editing: HX YZZ.

References
1. Weiss G, Goodnough LT. Anemia of chronic disease. New England Journal of Medicine. 2005; 352 (10):1011–23. PMID: 15758012
2. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010; 303(9):857–64. doi: 10.1001/jama.2010.206 PMID: 20197532
3. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer. 2001; 91(12):2214–21. PMID: 11413508
4. Raghavan M, Marik PE. Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. CHEST Journal. 2005; 127(1):295–307.
5. Tonelli M, Hemmelgarn B, Reisman T, Manns B, Reaume MN, Lloyd A, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. Canadian Medical Association Journal. 2009; 180(11):E62–E71. doi: 10.1503/cmaj.090470 PMID: 19407261
6. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003; 102(3):783–8. PMID: 12663437
7. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003; 101(7):2461–3. PMID: 1243676
8. Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. American journal of hematology. 2012; 87(4):392–400. doi: 10.1002/ajh.23110 PMID: 22290531
9. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. The Journal of clinical investigation. 2004; 113(9):1271–6. PMID: 15124018

10. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, et al. STAT3 is required for IL-6–gp130–dependent activation of hepcidin in vivo. Gastroenterology. 2007; 132(1):294–300. PMID: 17241879

11. Nicholson CK, Calvert JW. Hydrogen sulfide and ischemia–reperfusion injury. Pharmacological Research. 2010; 62(4):289–97. doi: 10.1016/j.phrs.2010.06.002 PMID: 20542117

12. Roviezoo F, Bertolino A, Sorrentino R, Tertizzi M, Matteis M, Calderone V, et al. Hydrogen sulfide inhalation ameliorated allergen induced airway hypereactivity by modulating mast cell activation. Pharmacological Research. 2015; 100:85–92. doi: 10.1016/j.phrs.2015.07.032 PMID: 26241177

13. Vandrillver MS, Snyder SH. Hydrogen sulfide: a gasotransmitter of clinical relevance. Journal of molecular medicine. 2012; 90(3):255–63. doi: 10.1007/s00109-012-0873-4 PMID: 22314625

14. Xin H, Wang M, Tang W, Shen Z, Miao L, Wu W, et al. Hydrogen sulfide attenuates inflammatory hepcidin by reducing IL-6 secretion and promoting SIRT1-mediated STAT3 deacetylation. Antioxidants & redox signaling. 2016; 24(2):70–83.

15. Whiteman M, Li L, Rose P, Tan C-H, Parkinson DB, Moore PK. The effect of hydrogen sulfide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. Antioxidants & redox signaling. 2010; 12(10):1147–54.

16. Rose P, Whiteman M, Moore PK, Zhu YZ. Bioactive S-alk(en)yl cysteine sulfoxide metabolites in the genus Allium: the chemistry of potential therapeutic agents. Natural products reports. 2005; 22(3):351–68. PMID: 16103435

17. Zheng Y, Liu H, Ma G, Yang P, Zhang L, Gu Y, et al. Determination of S-propargyl-cysteine in rat plasma by mixed-mode reversed-phase and cation-exchange HPLC–MS/MS method and its application to pharmacokinetic studies. Journal of pharmaceutical and biomedical analysis. 2011; 54 (5):1187–91. doi: 10.1016/j.jpba.2010.09.001 PMID: 20828607

18. Zheng Y, Xu J, Ma G, Zhang J, Zhu Q, Liu H, et al. Bioavailability and pharmacokinetics of S-propargyl-L-cysteine, a novel cardioprotective agent, after single and multiple doses in Beagle dogs. Xenobiota. 2012; 42(3):304–9. doi: 10.3109/00498254.2011.617848 PMID: 21961645

19. Wang Q, Wang X-L, Liu H-R, Rose P, Zhu Y-Z. Protective effects of cysteine analogues on acute myocardial ischemia: novel modulators of endogenous H2S production. Antioxidants & redox signaling. 2010; 12(10):1155–65.

20. Kan J, Guo W, Huang C, Bao G, Zhu Y, Zhu YZ. S-propargyl-cysteine, a novel water-soluble modulator of endogenous hydrogen sulfide, promotes angiogenesis through activation of signal transducer and activator of transcription 3. Antioxidants & redox signaling. 2014; 20(15):2303–16.

21. Gong Q-H, Wang Q, Pan L-L, Liu X-H, Xin H, Zhu Y-Z. S-propargyl-cysteine, a novel hydrogen sulfide-modulated agent, attenuates lipopolysaccharide-induced spatial learning and memory impairment: involvement of TNF signaling and NF-κB pathway in rats. Brain, behavior, and immunity. 2011; 25 (1):110–9. doi: 10.1016/biel.2010.09.001 PMID: 20828607

22. Siddhappuriwala JN, Hegde A, Ang AD, Zhu YZ, Bhatia M. Effects of S-propargyl-cysteine (SPRC) in caerulein-induced acute pancreatitis in mice. PloS one. 2012; 7(3):e32574. doi: 10.1371/journal.pone.0032574 PMID: 22396778

23. Shen Y, Shen Z, Miao L, Xin X, Lin S, Zhu Y, et al. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression. Antioxidants & redox signaling. 2015; 23(2):224–40.

24. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. The Journal of clinical investigation. 2002; 110(7):1037–44. PMID: 12370282

25. Sakamori R, Takehara T, Tatsumi T, Shigekawa M, Hikita H, Hiramatsu N, et al. STAT3 signaling within hepatocytes is required for anemia of inflammation in vivo. Journal of gastroenterology. 2010; 45(2):244–8. doi: 10.1007/s00535-009-0159-9 PMID: 20091060

26. Langdon JM, Yates SC, Fennou LK, McCranor BJ, Cheadle C, Xue QL, et al. Hepcidin-dependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation. American journal of hematology. 2014; 89(5):470–9. doi: 10.1002/ajh.23670 PMID: 24415655

27. Thomas MC, Maclusaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized Anemia in Patients With Diabetes A cross-sectional survey. Diabetes care. 2003; 26(4):1164–9. PMID: 12663591

28. Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflammatory bowel diseases. 2007; 13(12):1545–53. PMID: 17985376
29. Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. Journal of the American Society of Nephrology. 2005; 16(11):3403–10. PMID: 16162813

30. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. Journal of the American College of Cardiology. 2002; 39(11):1780–6. PMID: 12039491

31. Painter P, Moore G, Carlson L, Paul S, Myll J, Phillips W, et al. Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life. American Journal of Kidney Diseases. 2002; 39(6):1090–4. PMID: 11840365

32. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. The Lancet. 2009; 373(9674):1532–42.

33. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clinical Infectious Diseases. 2004; 38(6):1090–4. PMID: 15095212

34. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. Journal of Biological Chemistry. 2001; 276(11):7806–10. PMID: 11113131

35. Falzacappa MVV, Spasic MV, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007; 109(1):353–8. PMID: 16946298

36. Poli M, Girelli D, Campostrini N, Maccarinielli F, Finazzi D, Luscielli S, et al. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood. 2011; 117(3):997–1004. doi: 10.1182/blood-2010-06-289082 PMID: 21076043

37. Paul BY, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nature Chemical Biology. 2008; 4(1):33–41. PMID: 18026094

38. Song S-NJ, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti–IL-6 receptor antibody (tocilizumab) improves anemia in multicentric Castleman disease. Blood. 2010; 116(18):3627–34. doi: 10.1182/blood-2010-03-271791 PMID: 20644113

39. Li L, Rose P, Moore PK. Hydrogen sulfide and cell signaling. Annual Review of Pharmacology and Toxicology. 2011; 51:169–87. doi: 10.1146/annurev-pharmtox-010510-100505 PMID: 21210746

40. Zhang Q, Yuan L, Liu D, Wang J, Wang S, Zhang Q, et al. Hydrogen sulfide attenuates hypoxia-induced neurotoxicity through inhibiting microglial activation. Pharmacological Research. 2014; 84:32–44. doi: 10.1016/j.phrs.2014.04.009 PMID: 24788079

41. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proceedings of the National Academy of Sciences. 2007; 104(39):15560–5.

42. Miao L, Xin X, Xin H, Shen X, Zhu Y-Z. Hydrogen Sulfide Recruits Macrophage Migration by Integrin β1- Src- FAK/Pyk2- Rac Pathway in Myocardial Infarction. Scientific reports. 2016; 6.

43. Gong Q-H, Wang Q, Pan L-L, Liu X-H, Huang H, Zhu Y-Z. Hydrogen sulfide attenuates lipopolysaccharide-induced oxidative impairment: a pro-inflammatory pathway in rats. Pharmacology Biochemistry and Behavior. 2010; 96(1):52–8.

44. Liu Z, Han Y, Li L, Lu H, Meng G, Li X, et al. The hydrogen sulfide donor, GYY4137, exhibits anti-atherosclerotic activity in high fat fed apolipoprotein E−/− mice. British journal of pharmacology. 2013; 169(8):1795–809. doi: 10.1111/bph.12246 PMID: 23713790

45. Wang Q, Liu H-R, Mu Q, Rose P, Zhu YZ. S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway. Journal of Cardiovascular Pharmacology. 2009; 54(2):139–46. doi: 10.1097/FJC.0b013e3181ac8e12 PMID: 19546814

46. Pan L-L, Liu X-H, Gong Q-H, Zhu Y-Z. S-Propargyl-cysteine (SPRC) attenuated lipopolysaccharide-induced inflammatory response in H9c2 cells involved in a hydrogen sulfide-dependent mechanism. Amino acids. 2011; 41(1):205–15. doi: 10.1007/s00726-011-0834-1 PMID: 21308383